A vaccine highly expressing porcine interferon-alpha and PRRSV GP5 protein, preparation method and application thereof

By tandemly integrating the genes of PRRSV GP5 protein, self-cleaved polypeptide T2A and porcine interferon into the DC cell genome, a DC vaccine was prepared, which solved the problem of combining the preparation of vaccines against pig reproductive and respiratory syndrome in the prior art, and achieved efficient antiviral and immune regulation effects.

CN119258209BActive Publication Date: 2025-03-28SHANDONG XIANPU AIRUI TECH CO LTD
6 Cites 0 Cited by

Patent Information

Application Number
CN202411805195.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-12-10
Publication Date
2025-03-28
Estimated Expiration
2044-12-10

AI Technical Summary

Technical Problem

There is no vaccine against pig reproductive and respiratory syndrome by combining porcine interferon and PRRSV GP5 protein in the prior art, and the recombinantly expressed monomeric interferon has low antiviral activity and cannot have both antiviral and immune regulation.

Method used

By connecting the genes of PRRSV GP5 protein, self-cleaved polypeptide T2A and porcine interferon, stably integrating them into the DC cell genome, a DC vaccine is prepared. This vaccine can continuously express PRRSV GP5 antigen and release porcine interferon, activate cellular and humoral immunity, and exert anti-PRRSV effects.

Benefits of technology

This vaccine can improve the antiviral effect and therapeutic effect on pig reproductive and respiratory syndrome viruses, and significantly improve the immune effect and cure rate through continuous expression of antigens and release of interferons.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention provides a vaccine highly expressing porcine interferon-alpha and PRRSV GP5 protein, a preparation method and application thereof, belonging to the technical field of medical preparations, wherein the artificial nucleic acid sequence of the PRRSV GP5 protein is shown in SEQ ID NO.1, and the artificial nucleic acid sequence of the porcine interferon-alpha is shown in SEQ ID NO.3. The present invention connects the genes of PRRSV GP5 protein, self-cleaving polypeptide T2A and porcine interferon-alpha in series for the first time, and then stably integrates them into the DC cell genome to prepare a DC vaccine, which can continuously express PRRSV GP5 antigen, which can continuously stimulate and activate DC, and simultaneously activate cellular immunity and humoral immunity to play an anti-PRRSV role; the vaccine can release porcine interferon-alpha and directly inhibit the infection of PRRSV.
Need to check novelty before this filing date? Find Prior Art